FGF-23 and cardiovascular disease: Review of literature

Jasveen Batra, Rupinder Singh Buttar, Pardeep Kaur, Jacqueline Kreimerman, Michal L. Melamed

Research output: Contribution to journalReview articlepeer-review

35 Scopus citations


Purpose of review This review examines associations between fibroblast growth factor 23 (FGF-23) and cardiovascular disease. Recent findings FGF-23 is a hormone produced by osteocytes and osteoblasts that aids with phosphate excretion by the kidney and acts as a negative feedback regulator for activated vitamin D synthesis. Recent studies have found associations between elevated FGF-23 levels and a number of cardiovascular diseases, including hypertension, left ventricular hypertrophy, endothelial dysfunction, cardiovascular events and mortality. Conclusion Recent studies have explored the possible effects of FGF-23 on the cardiovascular system. In animal and observational human studies, there is a link between elevated FGF-23 levels and multiple cardiovascular outcomes, including hypertension, left ventricular hypertrophy and cardiovascular events and mortality. Further studies are required to evaluate whether decreasing FGF-23 levels improves cardiovascular outcomes.

Original languageEnglish (US)
Pages (from-to)423-429
Number of pages7
JournalCurrent Opinion in Endocrinology, Diabetes and Obesity
Issue number6
StatePublished - Oct 1 2016


  • Cardiovascular disease
  • Chronic kidney disease
  • Fibroblast growth factor 23
  • Phosphorus
  • Vitamin D

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Nutrition and Dietetics


Dive into the research topics of 'FGF-23 and cardiovascular disease: Review of literature'. Together they form a unique fingerprint.

Cite this